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Abstract:
Introduction: Patient agitation represents a significant challenge in the emergency department
(ED), a setting in which medical staff are working under pressure dealing with a diverse range of
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medical emergencies. The potential for escalation into aggressive behavior, putting patients, staff,
and others at risk, makes it imperative to address agitated behavior rapidly and efficiently. Time
constraints and limited access to specialist psychiatric support have in the past led to the strategy
of “restrain and sedate,” which was believed to represent the optimal approach; however, it is
increasingly recognized that more patient-centered approaches result in improved outcomes. The
objective of this review is to raise awareness of best practices for the management of agitation in
the ED and to consider the role of new pharmacologic interventions in this setting.
Discussion: The Best practices in Evaluation and Treatment of Agitation (BETA) guidelines
address the complete management of agitation, including triage, diagnosis, interpersonal calming
skills, and medicine choices. Since their publication in 2012, there have been further developments
in pharmacologic approaches for dealing with agitation, including both new agents and new modes
of delivery, which increase the options available for both patients and physicians. Newer modes of
delivery that could be useful in rapidly managing agitation include inhaled, buccal/sublingual and
intranasal formulations. To date, the only formulation administered via a non-intramuscular route
with a specific indication for agitation associated with bipolar or schizophrenia is inhaled loxapine.
Non-invasive formulations, although requiring cooperation from patients, have the potential to
improve overall patient experience, thereby improving future cooperation between patients and
healthcare providers.
Conclusion: Management of agitation in the ED should encompass a patient-centered approach,
incorporating non-pharmacologic approaches if feasible. Where pharmacologic intervention is
necessary, a cooperative approach using non-invasive medications should be employed where
possible.
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Copyright 2016 by the article author(s). This work is made available under the terms of the Creative
Commons Attribution4.0 license, http://creativecommons.org/licenses/by/4.0/
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Introduction: Patient agitation represents a significant challenge in the emergency department 
(ED), a setting in which medical staff are working under pressure dealing with a diverse range of 
medical emergencies. The potential for escalation into aggressive behavior, putting patients, staff, 
and others at risk, makes it imperative to address agitated behavior rapidly and efficiently. Time 
constraints and limited access to specialist psychiatric support have in the past led to the strategy 
of “restrain and sedate,” which was believed to represent the optimal approach; however, it is 
increasingly recognized that more patient-centered approaches result in improved outcomes. The 
objective of this review is to raise awareness of best practices for the management of agitation in the 
ED and to consider the role of new pharmacologic interventions in this setting. 
Discussion: The Best practices in Evaluation and Treatment of Agitation (BETA) guidelines 
address the complete management of agitation, including triage, diagnosis, interpersonal 
calming skills, and medicine choices. Since their publication in 2012, there have been further 
developments in pharmacologic approaches for dealing with agitation, including both new agents 
and new modes of delivery, which increase the options available for both patients and physicians. 
Newer modes of delivery that could be useful in rapidly managing agitation include inhaled, buccal/
sublingual and intranasal formulations. To date, the only formulation administered via a non-
intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia 
is inhaled loxapine. Non-invasive formulations, although requiring cooperation from patients, have 
the potential to improve overall patient experience, thereby improving future cooperation between 
patients and healthcare providers.
Conclusion: Management of agitation in the ED should encompass a patient-centered approach, 
incorporating non-pharmacologic approaches if feasible. Where pharmacologic intervention is 
necessary, a cooperative approach using non-invasive medications should be employed where 
possible. [West J Emerg Med. 2016;17(2):165–172.]
INTRODUCTION
Individuals with bipolar disorder or schizophrenia are 
vulnerable to episodes of agitation, which can be defined 
as excessive verbal and motor behavior, especially during 
exacerbations of their disease.1 Agitation associated with 
psychosis is a frequent reason for emergency department 
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(ED) visits by patients with psychiatric disorders, and requires 
immediate action to prevent escalation to a level that could 
put patients, staff, and others at risk.1 As specialist psychiatric 
support other than social work services is often not available 
in the emergency setting, agitated patients may often need to 
be medically evaluated and treated by emergency physicians. 
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The physician should, where possible, identify the underlying 
etiology of the agitation – whether due to an underlying non-
psychiatric medical condition or primarily due to a mental 
disorder – before deciding on an appropriate course of action 
and possible pharmacologic intervention.2
In the past, standard practice for intervening with an 
agitated patient frequently involved restraint and seclusion; 
however, this approach is associated with many negative 
outcomes.3 From the patient’s perspective, the approach 
does not recognize that many affected individuals are 
frightened, fragile, and vulnerable, with a history of 
traumatic experiences; while for others, their presentation 
in the ED may be their first experience in mental healthcare 
systems. A negative experience at this stage can potentially 
influence their future cooperation with healthcare workers 
and jeopardize future management of a potentially serious 
underlying condition. For the medical profession, the 
restraint and seclusion approach, although perceived by 
many to be efficient, is resource intensive as there is a 
requirement for one-to-one observation of a restrained or 
sedated patient. In addition, it is often associated with staff 
injuries, and it increases the length of time that individuals 
remain in the ED, compounding problems of overcrowding 
and boarding.3,4 The process of the “takedown” to place 
an individual in restraints may take a substantial amount 
of time, during which staff are at high risk of assaults and 
injuries. Furthermore, sedation can mask an underlying 
condition, thereby hindering accurate diagnosis.2
Guidelines are available to direct clinicians in all 
aspects of agitation management from triage through to 
pharmacologic choices. When pharmacologic intervention 
is deemed necessary, an array of therapeutic options 
administered via different routes now exists, providing both 
the patient and physician with treatment alternatives. The aim 
of this narrative review is to raise awareness of best practices 
for the management of agitation in the ED, and to consider 
the role of new pharmacologic interventions for patients with 
agitation associated with bipolar disorder or schizophrenia. 
It is recognized that physicians working in the ED must also 
deal with agitation occurring in association with dementia, 
delirium, and drug abuse, however, these areas are beyond the 
scope of this review.
METHODS
The content of this narrative review was based on 
information contained within the Best practices in Evaluation 
and Treatment of Agitation (BETA) guidelines with the addition 
of data on new pharmacologic interventions that were identified 
through literature searches of PubMed using combinations of the 
search terms “agitation,” “bipolar,” “schizophrenia,” “emergency 
care,” and “emergency department.” Articles were then hand 
searched. Additional data included in the review are based on 
product prescribing information.
DISCUSSION
Guideline Overview
Various guidelines exist for the management of agitation,5 
some of which provide direction for agitation associated with 
a particular disorder, such as bipolar disorder,6 or occurring in 
a particular setting, such as the intensive care unit.7 In 2012, 
the Project BETA guidelines were published by the American 
Association for Emergency Psychiatry,1 providing detailed 
guidance on various aspects of patient management including 
medical evaluation and triage, psychiatric assessment, verbal 
de-escalation of the agitated patient, psychopharmacologic 
approaches, and the use and avoidance of seclusion and 
restraint.2,3,8-10 In addition, the Centers for Medicaid Services 
Conditions of Participation for Hospitals include mandatory 
regulations on the use of seclusion and restraint. 
Medical Evaluation and Triage
Agitation can be caused by disparate medical and 
psychiatric conditions including head trauma, infection, thyroid 
disease, substance abuse/withdrawal, psychotic disorders, 
and depression.10 Identifying the etiology therefore represents 
a significant challenge, which is made more difficult by the 
immediate need to calm the patient to avoid escalation. 
Rating scales have been developed to measure agitation, 
including the single-item Behavioral Activity Rating Scale 
(BARS), the five-item Positive and Negative Syndrome Scale 
(PANSS) Excited Component (EC), and the more complex 
Overt Agitation Severity Scale.11-18 PANSS-EC and BARS have 
been successfully used as primary outcome measures in the 
commercial development of several agents for the indication of 
agitation associated with schizophrenia and/or bipolar mania. 
BARS is simple to use and does not require the participant/
patient to answer questions, so it is favored for purely pragmatic 
purposes and is also useful in a non-medical setting.
For agitated patients presenting in the ED, medical 
evaluation and triage should include a brief history and vital 
signs.10 Where possible, oxygen levels and blood glucose 
levels should also be obtained. Patients with loss of memory 
or disorientation, severe headache, extreme muscle stiffness 
or weakness, heat intolerance, unintentional weight loss, 
new-onset psychosis, or difficulty in breathing should be 
immediately evaluated by a clinician.10 Abnormal vital 
signs, overt trauma, slurred speech, unequally dilated pupils, 
lack of coordination, seizures, or hemiparesis also warrant 
immediate evaluation.10
If feasible, attempts at de-escalation should be made 
at this stage in order to gain the patient’s cooperation and 
participation in the evaluation. There may, however, be 
instances where patients require medication during the 
assessment to calm them enough to allow a thorough 
evaluation. Some patients may require medication, restraint, 
and increased behavioral support if the risk of violent behavior 
becomes high and a patient remains uncooperative.10 
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Determining whether there is a known psychiatric illness 
is an important aspect of triage and initial evaluation, as an 
underlying condition would influence subsequent treatment 
decisions. Agitation arising from a general medical condition 
should be suspected for cases of new-onset agitation and for 
patients with a concerning past medical history, or if the onset 
is outside the normal ranges of psychiatric disease. A workup 
for a general medical condition should aim to identify the 
most likely underlying causes.10 
Psychiatric Assessment
Severe agitation can preclude the ability for emergency 
physicians to conduct a complete psychiatric evaluation at 
the outset; however, a brief evaluation should be conducted 
to establish the most likely cause of the agitation.9 In many 
cases, the initial assessment can be conducted through visual 
observation of the patient during attempts at de-escalation, 
combined with verbal reports from other team and family 
members.9 Next, attempts should be made to establish if the 
patient has delirium, other cognitive impairment, intoxication 
or withdrawal, a known psychiatric condition, or another 
cause. When the patient is calm enough – either as a result 
of verbal de-escalation or initial medication – a formal 
psychiatric evaluation should be conducted.9 Of note, the goal 
of an emergency psychiatric assessment is not necessarily 
to obtain a definitive diagnosis, but instead it should aim to 
establish a reasonable differential diagnosis, identify issues 
related to safety of the patient and others, and develop a 
suitable treatment and disposition plan.9
Non-Pharmacologic Management
An important underlying principle of the Project 
BETA guidelines is that seclusion and restraint should be 
avoided, as this approach is associated with many negative 
outcomes.3,8 For patients and staff, injuries – both physical and 
psychological – often occur during restraint, which can have 
negative consequences that extend beyond the period during 
which the patient is restrained. Furthermore, restraint can 
damage short- and long-term patient–physician relationships. 
Restraining patients can also result in additional resource 
use and a longer time spent in the ED. For example, in 
a prospective evaluation of over 1,000 adults treated in 
the ED, use of restraint resulted in patients spending an 
additional 4.2 hours in the ED compared with those not 
requiring restraint.4 Reduced ED boarding can increase 
hospital revenue if bed capacity is effectively managed.19 
The need for additional staff for the restraint procedure 
and subsequent observation is time consuming, costly, and 
stops staff from performing other duties. Patients who have 
been sedated also spend longer in the ED, as it can be more 
challenging to admit or transfer a recently restrained patient 
or one who has been sedated.
Instead of restraint, where possible, initial attempts to 
calm the patient should focus on non-coercive approaches 
involving verbal engagement, establishment of collaborative 
relationship, and verbal de-escalation (Table 1).3 Key aspects 
of de-escalation include: respecting a patient’s personal 
space; avoiding provocation; establishing verbal contact and 
providing orientation and reassurance; communicating simply 
and concisely; identifying the patient’s wants and feelings; 
listening to what the patient is saying; setting clear limits; 
offering choices and optimism; and debriefing the patient if 
involuntary intervention has been necessary.3 As part of this 
strategy, non-verbal interventions, e.g. voluntary medication 
and environment planning, can also be useful. As discussed 
later, in situations where medication is taken voluntarily, some 
of the newer modes of administration – inhalation and rapid-
onset oral medications – may be more acceptable to patients 
than traditional injectable formulations. 
Implementation of non-coercive approaches may 
require changes in organizational culture and staff 
training;8,20 however, the benefits are widespread, 
including reduced resource use, costs, and staff and patient 
injuries, and better patient–physician relationships.4,19 
The advantages and disadvantages of non-pharmacologic 
approaches are outlined in Table 2.
Pharmacologic Management 
Management of agitation is multifaceted and 
pharmacologic interventions represent only one part of 
the overall approach. In some cases, agitation can be 
managed through non-pharmacologic approaches, such as 
verbal interventions and de-escalation; however, for many 
individuals some pharmacologic treatment will be necessary.2 
When choosing the optimal treatment, the provisional 
diagnosis should be taken into account (intoxication, 
psychiatric illness, delirium, head trauma, infection, etc.) and 
where possible the underlying etiology should be targeted. 
Consideration should also be given to the timing and extent 
of medication. Elderly patients pose special challenges in 
terms of potential comorbidities and potential drug–drug 
interactions, necessitating dosage adjustments. 
Early and excessively aggressive pharmacologic 
intervention can mask underlying conditions, delaying and 
impeding accurate diagnosis.2 However, delays in medication 
use can allow the agitation to escalate, putting the patient, 
staff, and others at increased risk of harm. Furthermore, if 
the agitation becomes markedly more pronounced, higher 
doses and more frequent administration of medication may 
become necessary. Taking these factors into account, the goal 
of pharmacologic intervention should be to calm the patient 
to allow assessment, avoiding sleep if possible. Sleeping 
or over-sedated patients can require additional monitoring, 
which increases the burden on available resources (such 
as the need for one-to-one observation, assistance in 
toileting, etc.), and can delay appropriate disposition. The 
Project BETA guidelines recommend that patients should 
be involved in the process of selecting the drug type and 
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administration route if possible. If the patient is able to 
cooperate with taking oral medications, these are preferred 
over intramuscular formulations.2 
Medications commonly used in the management of acute 
agitation include first- and second-generation antipsychotics, 
and benzodiazepines. Not all interventions and/or formulations 
have received U.S. Food and Drug Administration (FDA) 
approval for this use, and they also vary in terms of strength 
of the experimental evidence supporting their use. For patients 
with agitation associated with a psychiatric disorder, such as 
bipolar disorder or schizophrenia, antipsychotics are preferred 
over benzodiazepines because they address the underlying 
psychosis.2 If, however, an initial dose of an antipsychotic does 
not control the agitation, the addition of a benzodiazepine is 
recommended over an increased dose of the same antipsychotic 
or addition of a second antipsychotic.2 Moreover, in the case 
of acute withdrawal from alcohol or benzodiazepines the 
preferred medication intervention is a benzodiazepine, e.g. 
lorazepam; this is not a trivial consideration, as it is estimated 
that approximately half of all patients with schizophrenia have a 
comorbid drug- or alcohol-abuse problem.21
Desirable features of antipsychotics are rapid onset, 
control of aggressive behavior, reliability, and preservation of 
the physician–patient relationship.22,23 Intramuscular injection 
enables direct entry of the active agent into the systemic 
circulation through the muscle’s vasculature, providing 
the potential for rapid onset of action. The first-generation 
injectable antipsychotic haloperidol has long been used in the 
treatment of agitation in schizophrenia.2 When delivered via 
intramuscular injection, peak plasma levels of haloperidol 
are reached in ~20 minutes (Table 3).24 This rapid onset of 
action must be balanced against haloperidol’s adverse-event 
burden, including lengthened electrocardiogram QTc interval, 
extrapyramidal symptoms, and akathisia.23 Dystonic reactions, 
including laryngospasm, oculogyric crisis, and torticollis, 
are particularly frightening for patients, and can occur 12–24 
hours after administration.25 The occurrence of adverse effects 
such as these is an important consideration because they 
can complicate management and compromise future care as 
patients may be less willing to take medicines, particularly if 
they have experienced an acute dystonic reaction. 
Intramuscular preparations of the second-generation 
antipsychotics ziprasidone,26 olanzapine,27 and aripiprazole28 
have more favorable extrapyramidal side-effect profiles 
than haloperidol while providing similar effect sizes for the 
reduction of agitation.2,29 Intramuscular injections of these 
agents are approved by the FDA for treatment of acute agitation 
associated with schizophrenia (aripiprazole, olanzapine, 
and ziprasidone)26–28 and bipolar mania (olanzapine and 
aripiprazole)27,28 and they are now recommended over the first-
generation antipsychotics in guidelines.2 
One of the key disadvantages of intramuscular injections 
is that patients may resist, resulting in the need for manual 
immobilization, risking injury to healthcare providers, 
including inadvertent needlestick injuries. Furthermore, the 
use of force to immobilize the patient can result in mental 
trauma that has the potential to negatively affect immediate 
and future patient–physician relationships.
The disadvantages of intramuscular injections have 
led to the recommendation that non-invasive formulations 
should be used in situations where the patient is able to 
cooperate.2 Non-invasive formulations require at least 
some cooperation from patients but have the potential to 
prevent escalation and improve the experience of patients, 
and could be considered when negotiation is possible. 
Oral formulations of most first- and second-generation 
Behavioral intervention Patient scenario
Verbal de-escalation Should be attempted in all patients
Quiet unlocked room Patients in whom de-escalation alone was insufficient to reduce dangerousness enough to allow to remain 
in general care areas, and/or may need more time to regain control away from other patients
Locked seclusion If patients are considered an imminent danger to others but not themselves, and cannot tolerate or remain 
in a quiet unlocked room
Restraint If patients are considered an imminent danger to themselves, and cannot remain in a locked seclusion room 
without actively trying to injure themselves.
Advantages Disadvantages 
•	 Facilitates better short- and long-term patient–physician 
relationships
•	 Reduces staff and patient injuries associated with restraint 
and sedation
•	 May not be effective in all patients
•	 Requires some co-operation from the patient
•	 Reduces resource (clinical and staff) use
Table 1. Behavioral interventions for different scenarios involving patient agitation.
Table 2. Advantages and disadvantages of non-pharmacologic interventions for agitation.
Volume XVII, no. 2 : March 2016 169 Western Journal of Emergency Medicine
Zeller et al. Managing Schizophrenia and Bipolar Disorder Agitation
antipsychotics are available; however, administration results 
in entry to the systemic circulation via the portal system, 
absorption can be erratic, and onset of action is slower than 
for agents administered via intramuscular injection (Table 3).
Orally disintegrating formulations of olanzapine, 
risperidone, and aripiprazole have been developed, which 
dissolve with saliva in the mouth and can be swallowed 
without additional liquid.27,28,30 This can be beneficial for 
patients with dysphagia and also in patients who might divert 
the medication. However, this method of administration does 
not improve time to onset as the medication must still be 
swallowed, with absorption taking place lower in the gut.32 All 
three of these orally disintegrating antipsychotic formulations 
are bioequivalent to the regular oral tablets and provide 
similar efficacy and safety at the same doses.27,28,33,34 
Another orally disintegrating tablet formulation of an 
atypical antipsychotic that is available is sublingual asenapine,35 
which is approved by the FDA for the treatment of schizophrenia 
and for manic/mixed episodes associated with bipolar disorder. 
In contrast to the orally disintegrating tablets of olanzapine, 
risperidone, and aripiprazole, sublingual asenapine is absorbed 
in the oral mucosa and peak plasma concentration is reached 
in 30–60 minutes.35 Administration via this route has the 
advantage of avoiding first-pass metabolism; however, as with 
all oral medications, treatment requires patient cooperation. In 
a randomized, double-blind, placebo-controlled trial for acute 
agitation, sublingual asenapine was efficacious, with an effect 
size comparable to that observed in prior studies of intramuscular 
second-generation antipsychotics.36 However, sublingual 
asenapine is not approved by the FDA for acute agitation and its 
use for this indication would be considered off label.35
A recent addition to the armamentarium is inhaled loxapine, 
which is approved by the FDA for the acute treatment of 
agitation associated with schizophrenia or bipolar I disorder.31 
Loxapine is a first-generation antipsychotic, which has been 
available for many years as an oral formulation and has an 
established safety and efficacy profile.37 It has recently been 
reformulated at a lower dose as an inhaled powder that can 
be directly administered to the lungs. This results in rapid 
absorption into the systemic circulation with peak plasma 
levels being reached within two minutes of administration.31 
The efficacy and safety of inhaled loxapine for acute agitation 
were demonstrated in two Phase III clinical trials, one in 
schizophrenia and the second in bipolar mania.38,39 In these 
studies, the effect sizes were comparable to those observed in 
analogous studies of intramuscular injection of antipsychotics or 
Administration 
route Advantages32 Disadvantages32 Examples
Time to 
peak plasma 
concentration
Intramuscular Rapid systemic entry; patient 
cooperation not necessary
Invasive; can damage patient–
physician relationship
Haloperidol24 
Olanzapine27 
Aripiprazole28 
Ziprasidone26 
~20 minutes
15–45 minutes
1–3 hours
60 minutes
Inhaled Less invasive than intramuscular 
route and can improve patient 
experience. Enters alveoli for rapid 
entry into arterial circulation 
Requires patient cooperation 
Bronchospasm/ 
respiratory distress
Loxapine31 2 minutes
Oral
Standard 
tablets/
capsules/ 
solution
Less invasive than intramuscular 
route and can improve patient 
experience
Require patient cooperation; slow 
onset of action; enter systemic 
circulation via portal system resulting 
in potential for erratic absorption; 
can be diverted (“cheeking”)
Haloperidol24 
Olanzapine27 
Risperidone30 
Aripiprazole28 
Ziprasidone26 
2–6 hours
5–8 hours
~1 hour
3–5 hours
6–8 hours
Orally 
disintegrating 
tablets
Less invasive than intramuscular route 
and can improve patient experience. 
Less potential for diversion (“cheeking”) 
vs standard tablets/capsules; suitable 
for patients with dysphagia
Slow onset of action; enter systemic 
circulation via portal system resulting 
in potential for erratic absorption
Olanzapine27 
Risperidone30,33,34 
Aripiprazole28 
~6 hours
1–2 hours
3–5 hours
Buccal/
sublingual
Less invasive than intramuscular 
route and can improve patient 
experience; rapid absorption; 
avoids first-pass metabolism
Requires patient cooperation; needs 
to be taken correctly so that it is not 
swallowed, mitigated in part by the 
friability of the tablet
Sublingual 
asenapine35 
0.5–1.5 hours
Intranasal Less invasive than intramuscular 
route and can improve patient 
experience; rapid absorption; 
avoids first-pass metabolism
Requires patient cooperation. Intranasal 
midazolam32
10 minutes
Table 3. Advantages and disadvantages of different routes of administration.
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lorazepam.40 Of note, clinical effects, as measured by separation 
from placebo on the PANSS-EC, were observed as early as 
10 minutes after inhalation, the first time point that this was 
measured.38,39 Inhaled loxapine was generally well tolerated, 
with dysgeusia being the most common spontaneously reported 
adverse event. Extrapyramidal adverse events and akathisia 
were relatively rare; however, spirometry studies indicated 
inhaled loxapine can cause bronchospasm that has the potential 
to lead to respiratory distress and respiratory arrest. For this 
reason, inhaled loxapine is restricted to use in hospitals with 
access to facilities to deal with acute bronchospasm, and is only 
available through a restricted program under a risk-evaluation 
and mitigation strategy. It is worth noting that as inhaled 
loxapine is self-administered under medical supervision, it is 
unlikely to be suitable in situations where patients are actively 
refusing treatment.1 However, even a patient in restraints could 
conceivably use voluntarily self-administered medications, if 
one arm can be safely released. 
Midazolam – a water-soluble, fast-acting benzodiazepine 
– can be administered through various routes, including 
intranasally. Although not FDA approved for acute agitation, 
there has been interest in the potential use of this formulation 
for this indication.32 Intranasal midazolam is absorbed 
by the nasal mucosa and avoids first-pass metabolism. In 
children, intranasal midazolam induced calming within 
15 to 20 minutes.41 A caveat is that midazolam is chiefly 
used for sedation and has no antipsychotic effects; thus, 
like lorazepam, it would not ameliorate hallucinations or 
delusions, and will not treat the underlying psychosis that may 
be engendering the agitation. Although using a sedation agent 
alone might temporarily relieve agitation, there is the risk 
that upon awakening, if the psychotic symptoms still persist, 
agitation might quickly return. 
CONCLUSION
Agitation represents a significant challenge in the ED, 
a setting in which medical staff are working under extreme 
pressure and dealing with a diverse range of medical 
emergencies. The potential for agitation to escalate into 
aggressive behavior, putting patients, staff, and others at 
risk, means that it is important to address the behavior 
rapidly and efficiently to ensure the safety of all involved. 
Time constraints and limited access to specialist psychiatric 
support have in the past led to the somewhat draconian 
strategy of “restrain and sedate, ‘ which was believed to 
represent the optimal approach. It is increasingly recognized 
that more humane, patient-centered approaches result in 
improved short- and long-term outcomes, including fewer 
injuries, better therapeutic alliance, improved throughput, 
and reduced resource use and costs. The Project BETA 
guidelines address the complete management of agitation, 
including triage, diagnosis, interpersonal calming skills, and 
medicine choices. Since their publication in 2012, there have 
been further developments in pharmacologic approaches 
for dealing with agitation, including both new agents 
and new modes of delivery, which increase the options 
available to patients and physicians. Older interventions, 
such as intramuscular haloperidol, are – in the authors’ 
opinion – essentially now obsolete, because effective, yet 
more benign, FDA-approved injectable treatments are 
available instead.42,43 However, despite the availability of 
these injectable agents, non-invasive formulations, such as 
sublingual, inhaled, or intranasal agents, although requiring 
cooperation from patients, should be used whenever possible 
to improve the overall patient experience, thereby potentially 
improving future cooperation between patients and 
healthcare providers. At the present time inhaled loxapine is 
the only non-injectable option specifically approved by the 
FDA for this purpose; however, evidence is also available for 
sublingual asenapine and intranasal midazolam.
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